{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T04:32:54Z","timestamp":1792989174136,"version":"4.5.0"},"reference-count":63,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Health Services Research"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the utilization trends of authorized generics (AGs) within Medicare, evaluate differences in out\u2010of\u2010pocket (OOP) costs for Medicare beneficiaries between AGs and independent generics (IGs) when both were simultaneously available in the market, and estimate the adjusted mean difference in OOP costs between these generic types while controlling for potential confounders such as benefit phase and Medicare plan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Setting and Design<\/jats:title>\n                    <jats:p>This retrospective analysis examined Medicare Part D claims from 2012 to 2020, focusing on prescription\u2010level OOP expenditures. Claims were limited to periods in which both AGs and IGs for the same product were concurrently available. Three measures of cost were used: per claim, per 30 units dispensed, and per 30\u2010day supply.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources and Analytic Sample<\/jats:title>\n                    <jats:p>Using the 5% national Medicare Part D sample, linked to the FDA National Drug Code (NDC) Directory, AGs, IGs, and their market availability were identified. Plan information was retrieved from Medicare Plan Characteristics files. Sensitivity analyses applied winsorized OOP costs for outliers and a two\u2010part model for excess zeros.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Principal Findings<\/jats:title>\n                    <jats:p>\n                      AGs comprised a small share of prescriptions and declined from 3.65% in 2012 to 2.30% in 2020. Compared to IGs, AGs incurred higher OOP costs across all measures. Median per 30\u2010day supply costs were $3.19 for AGs and $1.96 for IGs. Multivariable regression showed IGs had lower adjusted mean OOP costs, with differences of $4.32 per claim, $8.99 per 30 units dispensed, and $6.49 per 30\u2010day supply (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). Results held across sensitivity analyses.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Despite their smaller market share, AGs are associated with consistently higher OOP costs than IGs. These cost differences have important implications for Medicare affordability and generic market competition. Policies that ensure timely independent generic market entry and prevent anticompetitive delay tactics may help reduce beneficiary financial burden and improve access to lower\u2010cost generics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/1475-6773.70159","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T07:57:14Z","timestamp":1788335834000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Analysis of the Utilization and Out\u2010of\u2010Pocket Costs of Authorized Generics and Independent Generics Among Medicare Beneficiaries"],"prefix":"10.1111","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7243-6573","authenticated-orcid":false,"given":"Arman","family":"Arabshomali","sequence":"first","affiliation":[{"name":"Department of Pharmacy Administration University of Mississippi School of Pharmacy  University Mississippi USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8857-1817","authenticated-orcid":false,"given":"Kaustuv","family":"Bhattacharya","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Administration University of Mississippi School of Pharmacy  University Mississippi USA"},{"name":"Center for Pharmaceutical Marketing and Management University of Mississippi School of Pharmacy  University Mississippi USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8792-4307","authenticated-orcid":false,"given":"Sujith","family":"Ramachandran","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Administration University of Mississippi School of Pharmacy  University Mississippi USA"},{"name":"Center for Pharmaceutical Marketing and Management University of Mississippi School of Pharmacy  University Mississippi USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Patel","sequence":"additional","affiliation":[{"name":"Indegene Inc.  Oxford Mississippi USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9241-6833","authenticated-orcid":false,"given":"John P.","family":"Bentley","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Administration University of Mississippi School of Pharmacy  University Mississippi USA"},{"name":"Center for Pharmaceutical Marketing and Management University of Mississippi School of Pharmacy  University Mississippi USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"J.Cubanski \u201cA Current Snapshot of the Medicare Part D Prescription Drug Benefit \u201d2025 KFF https:\/\/www.kff.org\/medicare\/issue\u2010brief\/a\u2010current\u2010snapshot\u2010of\u2010the\u2010medicare\u2010part\u2010d\u2010prescription\u2010drug\u2010benefit\/."},{"key":"e_1_2_10_3_1","unstructured":"N.Ochieng J.Cubanski andA.Damico \u201cMedicare Households Spend More on Health Care Than Other Households \u201d2024 KFF https:\/\/www.kff.org\/medicare\/issue\u2010brief\/medicare\u2010households\u2010spend\u2010more\u2010on\u2010health\u2010care\u2010than\u2010other\u2010households\/."},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.14211"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2010.0575"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2008.14.6.553"},{"issue":"1","key":"e_1_2_10_7_1","first-page":"45","article-title":"How Patient Cost\u2010Sharing Trends Affect Adherence and Outcomes","volume":"37","author":"Eaddy M. T.","year":"2012","journal-title":"Pharmacy & Therapeutics"},{"key":"e_1_2_10_8_1","unstructured":"\u201cGeneric Drugs Can Help Promote Health Equity \u201d2025 FDA https:\/\/www.fda.gov\/media\/173765\/download."},{"key":"e_1_2_10_9_1","unstructured":"\u201cExpanding the Use of Generic Drugs \u201d2010 ASPE http:\/\/aspe.hhs.gov\/reports\/expanding\u2010use\u2010generic\u2010drugs\u20100."},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.19355"},{"key":"e_1_2_10_11_1","unstructured":"\u201cGeneric Drug and Biosimilars Access & Savings in the U.S. Report \u201d2019 Association for Accessible Medicines https:\/\/accessiblemeds.org\/resources\/blog\/2019\u2010generic\u2010drug\u2010and\u2010biosimilars\u2010access\u2010savings\u2010us\u2010report\/."},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2022.01677"},{"key":"e_1_2_10_13_1","unstructured":"\u201cFDA List of Authorized Generic Drugs \u201d2025 FDA https:\/\/www.fda.gov\/drugs\/abbreviated\u2010new\u2010drug\u2010application\u2010anda\/fda\u2010list\u2010authorized\u2010generic\u2010drugs."},{"key":"e_1_2_10_14_1","unstructured":"\u201cAbbreviated New Drug Application (ANDA) \u201d2025 FDA https:\/\/www.fda.gov\/drugs\/types\u2010applications\/abbreviated\u2010new\u2010drug\u2010application\u2010anda."},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13426"},{"key":"e_1_2_10_16_1","unstructured":"R.Lal \u201cPatents and Exclusivity \u201d2015 https:\/\/www.fda.gov\/media\/92548\/download."},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12249\u2010018\u20101073\u20105"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp080086"},{"key":"e_1_2_10_19_1","unstructured":"M.Edlin \u201cWhat Are Authorized Generics?\u201d2019 https:\/\/www.managedhealthcareexecutive.com\/view\/what\u2010are\u2010authorized\u2010generics."},{"issue":"4","key":"e_1_2_10_20_1","first-page":"739","article-title":"Sword or Shield? An Overview and Competitive Analysis of the Marketing of Authorized Generics","volume":"62","author":"Zain S.","year":"2007","journal-title":"Food and Drug Law Journal"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.8450"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2021.5997"},{"key":"e_1_2_10_23_1","unstructured":"M. W.Hassan \u201cSenator Hassan Letter to GSK on Flovent Discontinuation \u201d2025 https:\/\/www.hassan.senate.gov\/imo\/media\/doc\/2025\u201006\u201027%20Hassan%20to%20GSK%20\u2010%20Copy_Redacted.pdf."},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2024.01058"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/1475\u20106773.14145"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP\u201024\u201000937"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/geroni\/igac059.2896"},{"key":"e_1_2_10_28_1","unstructured":"Center for Drug Evaluation and Research \u201cDrug Approvals and Databases \u201d2025 FDA https:\/\/www.fda.gov\/drugs\/development\u2010approval\u2010process\u2010drugs\/drug\u2010approvals\u2010and\u2010databases."},{"key":"e_1_2_10_29_1","unstructured":"ResDAC \u201cAmount Paid by Patient \u201d2024 https:\/\/resdac.org\/cms\u2010data\/variables\/amount\u2010paid\u2010patient."},{"key":"e_1_2_10_30_1","unstructured":"\u201cDrug Coverage Status Code \u201d2025 ResDAC https:\/\/resdac.org\/cms\u2010data\/variables\/drug\u2010coverage\u2010status\u2010code."},{"key":"e_1_2_10_31_1","unstructured":"\u201cQuantity Dispensed \u201d2025 ResDAC https:\/\/resdac.org\/cms\u2010data\/variables\/quantity\u2010dispensed."},{"key":"e_1_2_10_32_1","unstructured":"\u201cDays Supply (Part D) \u201d2025 ResDAC https:\/\/resdac.org\/cms\u2010data\/variables\/days\u2010supply\u2010part\u2010d."},{"key":"e_1_2_10_33_1","unstructured":"\u201cUsing Appropriate Price Indices for Expenditure Comparisons \u201d2025 AHRQ https:\/\/meps.ahrq.gov\/about_meps\/Price_Index.shtml."},{"key":"e_1_2_10_34_1","unstructured":"\u201cBEA Interactive Data Application \u201daccessed February 23 2025 https:\/\/apps.bea.gov\/iTable\/?reqid=19&step=2%23reqid%3D19&step=2&isuri=1&1921=survey."},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2024.30.12.1355"},{"key":"e_1_2_10_36_1","unstructured":"\u201cBenefit Phase of Part D Event \u201dResDAC accessed March 1 2025 https:\/\/resdac.org\/cms\u2010data\/variables\/benefit\u2010phase\u2010part\u2010d\u2010event."},{"key":"e_1_2_10_37_1","unstructured":"\u201cPlan Contract ID \u201dResDAC accessed March 1 2025 https:\/\/resdac.org\/cms\u2010data\/variables\/plan\u2010contract\u2010id."},{"key":"e_1_2_10_38_1","unstructured":"\u201cPlan Benefit Package ID \u201d2025 ResDAC https:\/\/resdac.org\/cms\u2010data\/variables\/plan\u2010benefit\u2010package\u2010id."},{"key":"e_1_2_10_39_1","unstructured":"\u201cFormulary Identification Number \u201dResDAC accessed March 2 2025 https:\/\/resdac.org\/cms\u2010data\/variables\/formulary\u2010identification\u2010number."},{"key":"e_1_2_10_40_1","unstructured":"\u201cCCW Formulary Drug Identifier \u201dResDAC accessed March 2 2025 https:\/\/resdac.org\/cms\u2010data\/variables\/ccw\u2010formulary\u2010drug\u2010identifier."},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.8406"},{"key":"e_1_2_10_42_1","unstructured":"\u201cGeneric Drugs \u201d2024 FDA https:\/\/www.fda.gov\/drugs\/buying\u2010using\u2010medicine\u2010safely\/generic\u2010drugs."},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1001\/virtualmentor.2014.16.2.pfor1\u20101402"},{"key":"e_1_2_10_44_1","unstructured":"G.Sparks A.Kirzinger A.Montero I.Valdes andL.Hamel \u201cPublic Opinion on Prescription Drugs and Their Prices \u201d2024 KFF https:\/\/www.kff.org\/other\/poll\u2010finding\/public\u2010opinion\u2010on\u2010prescription\u2010drugs\u2010and\u2010their\u2010prices\/."},{"key":"e_1_2_10_45_1","unstructured":"R.Preidt \u201cAlmost 13 Million Americans Per Year Skip Medications Due to Cost \u201d2021 https:\/\/www.healthday.com\/health\u2010news\/general\u2010health\/b\u201012\u20103\u2010almost\u201013\u2010million\u2010americans\u2010per\u2010year\u2010skip\u2010meds\u2010due\u2010to\u2010cost\u20102655910387.html."},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2016.1704"},{"key":"e_1_2_10_47_1","unstructured":"M.Dougherty \u201cThe Impacts of Changes in Prescription Drug Affordability and Accessibility on Patient Out\u2010of\u2010Pocket Costs and Emergency Health Events \u201d2024 The University of Utah http:\/\/umiss.idm.oclc.org\/login?url=https:\/\/www.proquest.com\/dissertations\u2010theses\/impacts\u2010changes\u2010prescription\u2010drug\u2010affordability\/docview\/3157834770\/se\u20102?accountid=14588."},{"key":"e_1_2_10_48_1","unstructured":"M.Dougherty B.Kim andF.Wilson \u201cThe Impact of Authorized Generic Insulin Lispro on Individual Out\u2010of\u2010Pocket Costs and Annual Affordability \u201d2025 AcademyHealth https:\/\/academyhealth.confex.com\/academyhealth\/2025arm\/meetingapp.cgi\/Paper\/72225."},{"key":"e_1_2_10_49_1","unstructured":"S.Bailey A.Burns D.Hartung et\u00a0al. \u201cReport for the Oregon Legislature | Generic Drug Report Pursuant to Senate Bill 844 (2021) \u201d2024 https:\/\/dfr.oregon.gov\/pdab\/Documents\/reports\/PDAB\u2010Generic\u2010Drug\u2010Report\u20102024.pdf."},{"key":"e_1_2_10_50_1","unstructured":"K.Goldman W.Cohen K.Grimm C.Bryan andR.Nelson \u201cAuthorized Generic Drugs: Short\u2010Term Effects and Long\u2010Term Impact: A Report of the Federal Trade Commission \u201d2011 https:\/\/www.ftc.gov\/sites\/default\/files\/documents\/reports\/authorized\u2010generic\u2010drugs\u2010short\u2010term\u2010effects\u2010and\u2010long\u2010term\u2010impact\u2010report\u2010federal\u2010trade\u2010commission\/authorized\u2010generic\u2010drugs\u2010short\u2010term\u2010effects\u2010and\u2010long\u2010term\u2010impact\u2010report\u2010federal\u2010trade\u2010commission.pdf."},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2017.4650"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102015\u201011\u2010680058"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2022.08.013"},{"key":"e_1_2_10_54_1","unstructured":"\u201cPay\u2010for\u2010Delay: How Drug Company Pay\u2010Offs Cost Consumers Billions \u201d2010 https:\/\/www.ftc.gov\/sites\/default\/files\/documents\/reports\/pay\u2010delay\u2010how\u2010drug\u2010company\u2010pay\u2010offs\u2010cost\u2010consumers\u2010billions\u2010federal\u2010trade\u2010commission\u2010staff\u2010study\/100112payfordelayrpt.pdf."},{"key":"e_1_2_10_55_1","unstructured":"S.Donthi M.Whorley A.Fix andJ.Brennan \u201c57% of Generic Drugs Are Not on 2022 Part D Generic Tiers \u201d2022 Avalere https:\/\/avalere.com\/insights\/57\u2010of\u2010generic\u2010drugs\u2010are\u2010not\u2010on\u20102022\u2010part\u2010d\u2010generic\u2010tiers."},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2018.7824"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.37765\/ajmc.2021.88701"},{"key":"e_1_2_10_58_1","unstructured":"\u201cGeneric Prices Are Falling but Seniors Are Paying More for Generic Drugs. What's Happening Here?\u201dAssociation for Accessible Medicines accessed March 6 2025 https:\/\/accessiblemeds.org\/resources\/blog\/generic\u2010prices\u2010falling\u2010seniors\u2010paying\u2010more\u2010whats\u2010happening\/."},{"key":"e_1_2_10_59_1","unstructured":"MedPAC \u201cThe Medicare Prescription Drug Program (Part D): Status Report \u201daccessed March 6 2025 https:\/\/www.medpac.gov\/wp\u2010content\/uploads\/import_data\/scrape_files\/docs\/default\u2010source\/reports\/mar19_medpac_ch14_sec.pdf."},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2019.00673"},{"key":"e_1_2_10_61_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2018.05476"},{"key":"e_1_2_10_62_1","doi-asserted-by":"publisher","DOI":"10.1093\/jlb\/lsab013"},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/1468\u20100009.12533"},{"key":"e_1_2_10_64_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.o2163"}],"container-title":["Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1475-6773.70159","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1475-6773.70159","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1475-6773.70159","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:37:55Z","timestamp":1792985875000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1475-6773.70159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":63,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1111\/1475-6773.70159"],"URL":"https:\/\/doi.org\/10.1111\/1475-6773.70159","archive":["Portico"],"relation":{},"ISSN":["0017-9124","1475-6773"],"issn-type":[{"value":"0017-9124","type":"print"},{"value":"1475-6773","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"assertion":[{"value":"2026-03-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70159"}}